Title:
Polycystic Ovary Syndrome Treatment Market, By Drug Class (Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, Diuretics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.
Polycystic ovary syndrome can be explained as set of symptoms such as insulin sensitivity, menstrual regulatory, infertility, acne, and excess body and facial hair, which occurs due to increased levels of male hormone i.e. androgens in females of child-bearing age (15 to 49 years). Polycystic ovary syndrome is an incurable diseases, however, it can be managed by various options such as lifestyle changes, reducing weight, and taking medicines.
Restraints of the Global Polycystic Ovary Syndrome Treatment Market
Major factors hampering the growth of the polycystic ovary syndrome treatment market during the forecast period constitutes of unavailability of FDA approved drugs, and alternative treatment options.
Key features of the study:
- This report provides in-depth analysis of the global polycystic ovary syndrome treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global polycystic ovary syndrome treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck & Co., Inc., AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc.
- Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The global polycystic ovary syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
- Global Polycystic Ovary Syndrome Treatment Market, By Drug Class:
- Oral contraceptives
- Insulin Sensitizing Agents
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Diuretics
- Global Polycystic Ovary Syndrome Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Polycystic Ovary Syndrome Treatment Market, By Geography:
- By Drug Class
- Oral contraceptives
- Insulin Sensitizing Agents
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Diuretics
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- By Drug Class
- Oral contraceptives
- Insulin Sensitizing Agents
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Diuretics
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class
- Oral contraceptives
- Insulin Sensitizing Agents
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Diuretics
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Drug Class
- Oral contraceptives
- Insulin Sensitizing Agents
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Diuretics
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East:
- By Drug Class
- Oral contraceptives
- Insulin Sensitizing Agents
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Diuretics
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class
- Oral contraceptives
- Insulin Sensitizing Agents
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Diuretics
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Addex Therapeutics Ltd.
- BIOCAD
- Merck & Co., Inc.
- AstraZeneca plc.
- Bristol Myers Squibb Co.
- Ferring Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals, Inc.
"*" marked represents similar segmentation in other categories in the respective section.
